Liposomes. Opportunities in drug delivery

Drugs

Volumn 54, Issue SUPPL. 4, 1997, Pages 8-14

  Allen, T M ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; DAUNORUBICIN; DOXORUBICIN; DRUG CARRIER; LIPOSOME;

CAPILLARY PERMEABILITY; CLINICAL TRIAL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG TARGETING; DRUG TUMOR LEVEL; HUMAN; INFECTION; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; META ANALYSIS; REVIEW;

EID: 0030681273     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199700544-00004     Document Type: Review

References (56)

1. 1. AD Bangham MM Standish JC Watkins 1965 Diffusion of univalent ions across the lamellae of swollen phospholipids J Mol Biol 13 238 52 5859039 10.1016/S0022-2836(65)80093-6 1:CAS:528:DyaF2MXkvVWru7g%3D Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 1965; 13: 238–52
2. 2. LD Mayer MB Bally PR Cullis 1986 Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient Biochim Biophys Acta 857 123 6 3964703 10.1016/0005-2736(86)90105-7 1:CAS:528:DyaL28XitlShu7c%3D Mayer LD, Bally MB, Cullis PR. Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. Biochim Biophys Acta 1986; 857: 123–6
3. 3. G Haran R Cohen LK Bar 1993 Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic week bases Biochim Biophys Acta 1151 201 315 8373796 10.1016/0005-2736(93)90105-9 1:CAS:528:DyaK2cXjsl2huw%3D%3D Haran G, Cohen R, Bar LK, et al. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic week bases. Biochim Biophys Acta 1993; 1151: 201–315
4. 4. B Ceh M Winterhalter PM Frederik 1997 Stealth® liposomes: from theory to product Adv Drug Deliv Rev 24 165 77 10.1016/S0169-409X(96)00456-5 1:CAS:528:DyaK2sXhvFansLs%3D Ceh B, Winterhalter M, Frederik PM, et al. Stealth® liposomes: from theory to product. Adv Drug Deliv Rev 1997; 24: 165–77
5. 5. KJ Hwang 1987 Liposome pharmacokinetics MJ Ostro Liposomes: from biophysics to therapeutics Marcel Dekker New York 109 56 Hwang KJ. Liposome pharmacokinetics. In: Ostro MJ, editor. Liposomes: from biophysics to therapeutics. New York: Marcel Dekker, 1987: 109–56
6. 6. TM Allen CB Hansen DEL Menezes De 1995 Pharmacokinetics of long circulating liposomes Adv Drug Deliv Rev 16 267 84 10.1016/0169-409X(95)00029-7 1:CAS:528:DyaK2MXpt1amt78%3D Allen TM, Hansen CB, De Menezes DEL. Pharmacokinetics of long circulating liposomes. Adv Drug Deliv Rev 1995; 16: 267–84
7. 7. A Gabizon R Catane B Uziely 1994 Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes Cancer Res 54 987 92 8313389 1:CAS:528:DyaK2cXhslegs70%3D Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994; 54: 987–92
8. 8. DS Alberts NR Bachur JL Holtzman 1971 The pharmacokinetics of daunomycin in man Clin Pharmacol Ther 12 96 104 5541137 1:STN:280:DyaE3M7gtVyrsg%3D%3D Alberts DS, Bachur NR, Holtzman JL. The pharmacokinetics of daunomycin in man. Clin Pharmacol Ther 1971; 12: 96–104
9. 9. DW Northfelt FJ Martin P Working 1996 Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumour localization, and safety in patients with AIDS-related Kaposi’s sarcoma J Clin Pharmacol 36 55 63 8932544 1:CAS:528:DyaK28Xhs1egt7s%3D Northfelt DW, Martin FJ, Working P, et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumour localization, and safety in patients with AIDS-related Kaposi’s sarcoma. J Clin Pharmacol 1996; 36: 55–63
10. 10. PS Gill BM Espina F Muggia 1995 Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin J Clin Oncol 13 996 1003 7707129 1:STN:280:DyaK2M3it1egsw%3D%3D Gill PS, Espina BM, Muggia F, et al. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol 1995; 13: 996–1003
11. 11. JW Cowens PJ Creaven WR Greco 1993 Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes) Cancer Res 53 2796 802 8504422 1:STN:280:DyaK3s3nvVKkuw%3D%3D Cowens JW, Creaven PJ, Greco WR, et al. Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes). Cancer Res 1993; 53: 2796–802
12. 12. AL Klibanov K Maruyama VP Torchilin 1990 Amphipathic polyethylene glycols effectively prolong the circulation time of liposomes FEBS Lett 268 235 7 2384160 10.1016/0014-5793(90)81016-H 1:CAS:528:DyaK3cXmtFOqtbc%3D Klibanov AL, Maruyama K, Torchilin VP, et al. Amphipathic polyethylene glycols effectively prolong the circulation time of liposomes. FEBS Lett 1990; 268: 235–7
13. 13. MC Woodle DD Lasic 1992 Sterically stabilized liposomes Biochim Biophys Acta 1113 171 99 1510996 10.1016/0304-4157(92)90038-C 1:CAS:528:DyaK38XltlOnu78%3D Woodle MC, Lasic DD. Sterically stabilized liposomes. Biochim Biophys Acta 1992; 1113: 171–99
14. 14. TM Allen 1994 The use of glycolipids and hydrophilic polymers in avoiding rapid uptake of liposomes by the mononuclear phagocyte system Adv Drug Deliv Rev 13 285 309 10.1016/0169-409X(94)90016-7 1:CAS:528:DyaK2cXisl2qs7c%3D Allen TM. The use of glycolipids and hydrophilic polymers in avoiding rapid uptake of liposomes by the mononuclear phagocyte system. Adv Drug Deliv Rev 1994; 13: 285–309
15. 15. G Blume G Cevc 1990 Liposomes for the sustained drug release in vivo Biochim Biophys Acta 1029 91 7 2223816 10.1016/0005-2736(90)90440-Y 1:CAS:528:DyaK3cXmtlOktrk%3D Blume G, Cevc G. Liposomes for the sustained drug release in vivo. Biochim Biophys Acta 1990; 1029: 91–7
16. 16. J Senior C Delgado D Fisher 1991 Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles Biochim Biophys Acta 1062 77 82 1998713 10.1016/0005-2736(91)90337-8 1:CAS:528:DyaK3MXht1yqtLw%3D Senior J, Delgado C, Fisher D, et al. Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles. Biochim Biophys Acta 1991; 1062: 77–82
17. 17. TM Allen C Hansen 1991 Pharmacokinetics of stealth versus conventional liposomes: effect of dose Biochim Biophys Acta 1068 133 41 1911826 10.1016/0005-2736(91)90201-I 1:CAS:528:DyaK3MXms1ehsrY%3D Allen TM, Hansen C. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim Biophys Acta 1991; 1068: 133–41
18. 18. D Papahadjopoulos TM Allen A Gabizon 1991 Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy Proc Natl Acad Sci USA 88 11460 4 1763060 10.1073/pnas.88.24.11460 1:CAS:528:DyaK38XmslWjsg%3D%3D Papahadjopoulos D, Allen TM, Gabizon A, et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 1991; 88: 11460–4
19. 19. J Senior JC Crawley G Gregoriadis 1985 Tissue distribution of liposomes exhibiting long half-lives in the circulation after intravenous injection Biochim Biophys Acta 839 1 8 3978117 10.1016/0304-4165(85)90174-6 1:CAS:528:DyaL2MXit1Gqurw%3D Senior J, Crawley JC, Gregoriadis G. Tissue distribution of liposomes exhibiting long half-lives in the circulation after intravenous injection. Biochim Biophys Acta 1985; 839: 1–8
20. 20. CR Alving NM Wassef 1992 Complement-dependent phagocytosis of liposomes: suppression by ‘Stealth’ lipids J Liposome Res 2 383 95 10.3109/08982109209010216 1:CAS:528:DyaK3sXms1KlsA%3D%3D Alving CR, Wassef NM. Complement-dependent phagocytosis of liposomes: suppression by ‘Stealth’ lipids. J Liposome Res 1992; 2: 383–95
21. 21. D Aragnol L Leserman 1986 Immune clearance of liposomes inhibited by an anti-Fc receptor antibody in vivo Proc Natl Acad Sci USA 83 2699 703 3458229 10.1073/pnas.83.8.2699 1:CAS:528:DyaL28Xit1eitL4%3D Aragnol D, Leserman L. Immune clearance of liposomes inhibited by an anti-Fc receptor antibody in vivo. Proc Natl Acad Sci USA 1986; 83: 2699–703
22. 22. A Chonn SC Semple PR Cullis 1992 Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes J Biol Chem 267 18759 65 1527006 1:CAS:528:DyaK38XltFygsLk%3D Chonn A, Semple SC, Cullis PR. Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. J Biol Chem 1992; 267: 18759–65
23. 23. DD Lasic FJ Martin A Gabizon 1991 Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times Biochim Biophys Acta 1070 187 92 1751525 10.1016/0005-2736(91)90162-2 1:CAS:528:DyaK38Xisl2kug%3D%3D Lasic DD, Martin FJ, Gabizon A, et al. Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times. Biochim Biophys Acta 1991; 1070: 187–92
24. 24. VP Torchilin VG Omelyanenko MI Papisov 1995 Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer coated liposome longevity Biochim Biophys Acta 1195 11 20 Torchilin VP, Omelyanenko VG, Papisov MI, et al. Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer coated liposome longevity. Biochim Biophys Acta 1995; 1195: 11–20
25. 25. JR Silvius M J Zuckermann 1993 Interbilayer transfer of phospholipid-anchored macromolecules via monomer diffusion Biochemistry 32 3153 61 7681327 10.1021/bi00063a030 1:CAS:528:DyaK3sXisV2rtLo%3D Silvius JR, Zuckermann M J. Interbilayer transfer of phospholipid-anchored macromolecules via monomer diffusion. Biochemistry 1993; 32: 3153–61
26. 26. EA Forssen R Male-Brune JP Adler-Moore 1996 Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) with tumor tissue Cancer Res 56 2066 75 8616852 1:CAS:528:DyaK28Xis1ektL4%3D Forssen EA, Male-Brune R, Adler-Moore JP, et al. Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) with tumor tissue. Cancer Res 1996; 56: 2066–75
27. 27. J Vaage E Barberá-Guillem R Abra 1994 Tissue distribution and therapeutic effect on intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts Cancer 73 1478 84 8111716 10.1002/1097-0142(19940301)73:5<1478::AID-CNCR2820730526>3.0.CO;2-1 1:CAS:528:DyaK2cXktVSgtLc%3D Vaage J, Barberá-Guillem E, Abra R, et al. Tissue distribution and therapeutic effect on intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. Cancer 1994; 73: 1478–84
28. 28. J Vaage D Donovan P Uster 1997 Tumour uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma Br J Cancer 75 482 6 9052397 10.1038/bjc.1997.84 1:CAS:528:DyaK2sXhslWisb4%3D Vaage J, Donovan D, Uster P, et al. Tumour uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma. Br J Cancer 1997; 75: 482–6
29. 29. HF Dvorak JA Nagy JT Dvorak 1988 Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules Am J Pathol 133 95 109 2459969 1:STN:280:DyaL1M%2FitlCksQ%3D%3D Dvorak HF, Nagy JA, Dvorak JT, et al. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 1988; 133: 95–109
30. 30. F Yuan M Leunig SK Huang 1994 Microvascular permeability and interstitial penetration of sterically stabilized (Stealth) liposomes in a human tumor xenograft Cancer Res 54 3352 6 8012948 1:CAS:528:DyaK2cXltFOmsr8%3D Yuan F, Leunig M, Huang SK, et al. Microvascular permeability and interstitial penetration of sterically stabilized (Stealth) liposomes in a human tumor xenograft. Cancer Res 1994; 54: 3352–6
31. 31. NZ Wu D Da TL Rudoll 1993 Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumour tissue Cancer Res 53 3765 70 8339289 1:CAS:528:DyaK3sXmtlertLw%3D Wu NZ, Da D, Rudoll TL, et al. Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumour tissue. Cancer Res 1993; 53: 3765–70
32. 32. B Uziely S Jeffers R Isacson 1995 Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies J Clin Oncol 13 1777 85 7602367 1:STN:280:DyaK2MzisFyqug%3D%3D Uziely B, Jeffers S, Isacson R, et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995; 13: 1777–85
33. 33. JR Bogner U Kronawitter B Rolinski 1994 Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi’s sarcoma J Acquir Immune Defic Syndr 7 463 8 8158540 1:STN:280:DyaK2c3htVeksw%3D%3D Bogner JR, Kronawitter U, Rolinski B, et al. Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi’s sarcoma. J Acquir Immune Defic Syndr 1994; 7: 463–8
34. 34. F-D Goebel D Goldstein M Goos 1996 Efficacy and safety of Stealth® lipsomal doxorubicin in AIDS-related Kaposi’s sarcoma Br J Cancer 73 989 94 8611437 10.1038/bjc.1996.193 1:CAS:528:DyaK28XjtFKhu78%3D Goebel F-D, Goldstein D, Goos M, et al. Efficacy and safety of Stealth® lipsomal doxorubicin in AIDS-related Kaposi’s sarcoma. Br J Cancer 1996; 73: 989–94
35. 35. M Harrison D Tomlinson S Stewart 1995 Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi’s sarcoma J Clin Oncol 13 914 20 7707119 1:STN:280:DyaK2M3it1eiuw%3D%3D Harrison M, Tomlinson D, Stewart S. Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi’s sarcoma. J Clin Oncol 1995; 13: 914–20
36. 36. AT Horowitz Y Barenholz AA Gabizon 1992 In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release Biochim Biophys Acta 1109 203 9 1520697 10.1016/0005-2736(92)90084-Y 1:CAS:528:DyaK38XmtF2qs74%3D Horowitz AT, Barenholz Y, Gabizon AA. In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release. Biochim Biophys Acta 1992; 1109: 203–9
37. 37. T Siegal A Horowitz A Gabizon 1995 Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy J Neurosurg 83 1029 37 7490617 10.3171/jns.1995.83.6.1029 1:STN:280:DyaK28%2Fos1yksg%3D%3D Siegal T, Horowitz A, Gabizon A. Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J Neurosurg 1995; 83: 1029–37
38. 38. Bogner JR, Goebel F-D. Efficacy of Dox-SL (Stealth® liposomal doxorubicin) in the treatment of advanced AIDS-related Kaposi’s sarcoma. In: Lasic D, Martin F, editors. Boca Raton (FL): CRC Press, 1995: 267–81
39. 39. M Ranson K O’Bryne J Carmichael 1996 Phase II dose-finding trial of DOX-SL (Stealth® liposomal doxorubicin HCl) in the treatment of advanced breast cancer Proc Am Soc Clin Oncol 15 124 Ranson M, O’Bryne K, Carmichael J, et al. Phase II dose-finding trial of DOX-SL (Stealth® liposomal doxorubicin HCl) in the treatment of advanced breast cancer. Proc Am Soc Clin Oncol 1996; 15: 124
40. 40. F Muggia J Hainsworth S Jeffers 1996 Liposomal doxorubicin (Doxil) is active against refractory ovarian cancer Proc Am Soc Clin Oncol 15 287 Muggia F, Hainsworth J, Jeffers S, et al. Liposomal doxorubicin (Doxil) is active against refractory ovarian cancer. Proc Am Soc Clin Oncol 1996; 15: 287
41. 41. F Muggia JD Hainsworth S Jeffers 1997 Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation J Clin Oncol 15 987 93 9060537 1:CAS:528:DyaK2sXitFCgs7k%3D Muggia F, Hainsworth JD, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997; 15: 987–93
42. 42. DM Vail LD Kravis AJ Cooley 1997 Preclinical trial of doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumors Cancer Chemother Pharmacol 39 410 6 9054954 10.1007/s002800050591 1:STN:280:DyaK2s3gslKlsw%3D%3D Vail DM, Kravis LD, Cooley AJ, et al. Preclinical trial of doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumors. Cancer Chemother Pharmacol 1997; 39: 410–6
43. 43. JR Eckardt E Campbell HA Burries 1994 A phase II trial of DaunoXome, liposome encapsulated daunorubicin, in patients with metastatic adenocarcinoma of the colon Am J Clin Oncol Cancer Clin Trials 17 498 501 1:STN:280:DyaK2M%2FmslOlsA%3D%3D Eckardt JR, Campbell E, Burries HA, et al. A phase II trial of DaunoXome, liposome encapsulated daunorubicin, in patients with metastatic adenocarcinoma of the colon. Am J Clin Oncol Cancer Clin Trials 1994; 17: 498–501
44. 44. J Tollemar K Hockersted BC Ericzon 1995 Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients: a randomized, placebo controlled study Transplantation 59 45 50 7839427 10.1097/00007890-199501150-00009 1:STN:280:DyaK2M7ktFeltw%3D%3D Tollemar J, Hockersted K, Ericzon BC, et al. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients: a randomized, placebo controlled study. Transplantation 1995; 59: 45–50
45. 45. V Heinemann B Kahny A Debus 1994 Pharmacokinetics of liposomal amphotericin B (AmBisome) versus other lipid based formulations Bone Marrow Transplant 14 S8 9 7703929 Heinemann V, Kahny B, Debus A, et al. Pharmacokinetics of liposomal amphotericin B (AmBisome) versus other lipid based formulations. Bone Marrow Transplant 1994; 14: S8–9
46. 46. R Russo LC Nigro S Minniti 1996 Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome) J Infect 32 133 7 8708370 10.1016/S0163-4453(96)91343-2 1:STN:280:DyaK28zjt1KgsQ%3D%3D Russo R, Nigro LC, Minniti S, et al. Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome). J Infect 1996; 32: 133–7
47. 47. IAJM Bakker-Woudenberg AF Lokerse MT Kate ten 1992 Enhanced localization of liposomes with prolonged blood circulation time in infected lung tissue Biochim Biophys Acta 1138 318 26 1532911 10.1016/0925-4439(92)90010-K 1:CAS:528:DyaK38Xit1Wntb4%3D Bakker-Woudenberg IAJM, Lokerse AF, ten Kate MT, et al. Enhanced localization of liposomes with prolonged blood circulation time in infected lung tissue. Biochim Biophys Acta 1992; 1138: 318–26
48. 48. IAJM Bakker-Woudenberg AF Lokerse MT Kate ten 1993 Liposomes with prolonged blood circulation and selective localization in Klebsiella pneumoniae-infected lung tissue J Infect Dis 168 164 71 8515105 10.1093/infdis/168.1.164 1:STN:280:DyaK3s3psVemsA%3D%3D Bakker-Woudenberg IAJM, Lokerse AF, ten Kate MT, et al. Liposomes with prolonged blood circulation and selective localization in Klebsiella pneumoniae-infected lung tissue. J Infect Dis 1993; 168: 164–71
49. 49. S Marie de R Janknegt IAJM Bakker-Woudenberg 1994 Clinical use of liposomal and lipid-complexed amphotericin B Antimicrob Chemother 33 907 16 10.1093/jac/33.5.907 de Marie S, Janknegt R, Bakker-Woudenberg IAJM. Clinical use of liposomal and lipid-complexed amphotericin B. Antimicrob Chemother 1994; 33: 907–16
50. 50. A Vertut-Croquin J Bolard M Chabbert 1983 Differences in the interaction of the polyene antibiotic amphotericin B with cholesterol-or ergosterol-containing phospholipid vesicles. A circular dichroism and permeability study Biochemistry 22 2939 44 6871175 10.1021/bi00281a024 1:CAS:528:DyaL3sXitV2ls7w%3D Vertut-Croquin A, Bolard J, Chabbert M, et al. Differences in the interaction of the polyene antibiotic amphotericin B with cholesterol-or ergosterol-containing phospholipid vesicles. A circular dichroism and permeability study. Biochemistry 1983; 22: 2939–44
51. 51. RT Mehta G Lopez-Berestein R Hopfer 1984 Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells Biochim Biophys Acta 770 230 4 6696909 10.1016/0005-2736(84)90135-4 1:CAS:528:DyaL2cXhsVCqs7o%3D Mehta RT, Lopez-Berestein G, Hopfer R, et al. Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells. Biochim Biophys Acta 1984; 770: 230–4
52. 52. L Embree KA Gelmon A Lohr 1993 Chromatographic analysis and pharmacokinetics of liposome-encapsulated doxorubicin in non-small-cell lung cancer patients J Pharmaceut Sci 82 627 34 10.1002/jps.2600820617 1:CAS:528:DyaK3sXksVSit7o%3D Embree L, Gelmon KA, Lohr A, et al. Chromatographic analysis and pharmacokinetics of liposome-encapsulated doxorubicin in non-small-cell lung cancer patients. J Pharmaceut Sci 1993; 82: 627–34
53. 53. IJ Fidler ES Kleinerman 1994 Clinical application of phospholipid liposomes containing macrophage activators for therapy of cancer metastasis Adv Drug Deliv Rev 13 325 40 10.1016/0169-409X(94)90018-3 Fidler IJ, Kleinerman ES. Clinical application of phospholipid liposomes containing macrophage activators for therapy of cancer metastasis. Adv Drug Deliv Rev 1994; 13: 325–40
54. 54. E Abraham YC Park P Covington 1996 Liposomal prostaglandin E(l) in acute respiratory distress syndrome: a placebo controlled, randomized, double blind, multicenter clinical trial Crit Care Med 24 10 5 8565513 10.1097/00003246-199601000-00005 1:STN:280:DyaK287mtVKqug%3D%3D Abraham E, Park YC, Covington P, et al. Liposomal prostaglandin E(l) in acute respiratory distress syndrome: a placebo controlled, randomized, double blind, multicenter clinical trial. Crit Care Med 1996; 24: 10–5
55. 55. LD Mayer K Gelmon PR Cullis 1995 Preclinical and clinical studies with liposomal vincristine S Hirota Progress in drug delivery Biomedical Research Foundation Tokyo 151 61 Vol. 4 Mayer LD, Gelmon K, Cullis PR, et al. Preclinical and clinical studies with liposomal vincristine. In: Hirota S, editor. Progress in drug delivery. Vol. 4. Tokyo: Biomedical Research Foundation, 1995: 151–61
56. 56. TM Allen EH Moase 1996 Therapeutic opportunities for targeted liposomal drug delivery Adv Drug Deliv Rev 21 117 33 10.1016/S0169-409X(96)00402-4 1:CAS:528:DyaK28XmvFamsrc%3D Allen TM, Moase EH. Therapeutic opportunities for targeted liposomal drug delivery. Adv Drug Deliv Rev 1996; 21: 117–33